Literature DB >> 24649332

Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases.

Tsubasa Watanabe1, Takashi Mizowaki1, Yoshiki Arakawa2, Yusuke Iizuka1, Kengo Ogura1, Katsuyuki Sakanaka1, Susumu Miyamoto2, Masahiro Hiraoka1.   

Abstract

Pineal parenchymal tumor of intermediate differentiation (PPTID) is a rare disease, first classified by the World Health Organization in 2000. The number of available studies on the treatment of PPTID is currrently limited and the optimal management for this disease has not yet been determined. We retrospectively evaluated the treatment outcomes for PPTID at our institute and analyzed the roles of radiation therapy and chemotherapy for this disease. The clinical data on five patients diagnosed with PPTID since 2000 were retrospectively reviewed. Patients with cerebrospinal dissemination at diagnosis received biopsy-only surgery, craniospinal and whole-ventricular irradiation and chemotherapy. Patients with locally limited disease at diagnosis received local or whole-ventricular irradiation after surgery. The median relapse-free and overall survival were 72.9 and 94.1 months, respectively. Two of the five patients developed a relapse of cerebrospinal dissemination after treatment and succumbed to the disease. All the patients who received both craniospinal and whole-ventricular irradiation exhibited evidence of cerebral white matter abnormalities in magnetic resonance imaging and developed neurocognitive disorders after treatment. Although PPTID may be aggressive and has cerebrospinal fluid seeding potential, PPTID patients may survive long-term, even after recurrence. Considering the long survival time and the late adverse effects due to intensive treatment, the irradiation field and usage of chemotherapy after surgery require optimization.

Entities:  

Keywords:  chemotherapy; pineal parenchymal tumor; pineal parenchymal tumor of intermediate differentiation; radiation therapy; surgery

Year:  2013        PMID: 24649332      PMCID: PMC3917789          DOI: 10.3892/mco.2013.231

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  26 in total

1.  Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

Authors:  Xing Gong; Philip H Schwartz; Mark E Linskey; Daniela A Bota
Journal:  Neurology       Date:  2011-02-23       Impact factor: 9.910

2.  IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.

Authors:  Atsushi Natsume; Dai Ishii; Toshihiko Wakabayashi; Takaya Tsuno; Hisashi Hatano; Masaaki Mizuno; Jun Yoshida
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

3.  Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group.

Authors:  Tomokazu Aoki; Jun A Takahashi; Tetsuya Ueba; Natsuo Oya; Masahiro Hiraoka; Kunihiko Matsui; Tsugiya Fukui; Yasuaki Nakashima; Masatsune Ishikawa; Nobuo Hashimoto
Journal:  J Neurosurg       Date:  2006-09       Impact factor: 5.115

Review 4.  Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases.

Authors:  A Jouvet; G Saint-Pierre; F Fauchon; K Privat; E Bouffet; M M Ruchoux; L Chauveinc; M Fèvre-Montange
Journal:  Brain Pathol       Date:  2000-01       Impact factor: 6.508

5.  Capillary loss precedes the cognitive impairment induced by fractionated whole-brain irradiation: a potential rat model of vascular dementia.

Authors:  William R Brown; Robert M Blair; Dixon M Moody; Clara R Thore; Stephanie Ahmed; Michael E Robbins; Kenneth T Wheeler
Journal:  J Neurol Sci       Date:  2007-02-20       Impact factor: 3.181

6.  Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.

Authors:  R J Packer; B Lange; J Ater; H S Nicholson; J Allen; R Walker; M Prados; R Jakacki; G Reaman; M N Needles
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

7.  Combination chemotherapy (cisplatin, vinblastin) and low-dose irradiation in the treatment of pineal parenchymal cell tumors.

Authors:  M Kurisaka; M Arisawa; T Mori; T Sakamoto; M Seike; K Mori; T Okada; H Wakiguchi; T Kurashige
Journal:  Childs Nerv Syst       Date:  1998-10       Impact factor: 1.475

Review 8.  Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy.

Authors:  J R Crossen; D Garwood; E Glatstein; E A Neuwelt
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

9.  Structural and ultrastructural characteristics of human pineal gland, and pineal parenchymal tumors.

Authors:  A Jouvet; M Fèvre-Montange; R Besançon; E Derrington; G Saint-Pierre; M F Belin; J Pialat; C Lapras
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors.

Authors:  Johannes Lutterbach; François Fauchon; Steven E Schild; Susan M Chang; Axel Pagenstecher; Benedikt Volk; Christoph Ostertag; Felix Momm; Anne Jouvet
Journal:  Neurosurgery       Date:  2002-07       Impact factor: 4.654

View more
  7 in total

1.  Revisiting the metastatic potential of childhood pineal parenchymal tumor of intermediate differentiation: a case report.

Authors:  Navneet Singla; Ankur Kapoor; Sivashanmugam Dhandapani; B D Radotra; Debajyoti Chatterjee
Journal:  Childs Nerv Syst       Date:  2016-05-25       Impact factor: 1.475

Review 2.  Pineal parenchymal tumor of intermediate differentiation: a systematic review and contemporary management of 389 cases reported during the last two decades.

Authors:  Hajime Takase; Reo Tanoshima; Navneet Singla; Yoshihiko Nakamura; Tetsuya Yamamoto
Journal:  Neurosurg Rev       Date:  2021-10-20       Impact factor: 3.042

3.  Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database.

Authors:  Panagiotis Kerezoudis; Yagiz Ugur Yolcu; Nadia N Laack; Michael W Ruff; Soumen Khatua; David J Daniels; Terry C Burns; Sani H Kizilbash
Journal:  Neurooncol Adv       Date:  2022-04-17

4.  Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.

Authors:  David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

5.  Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade.

Authors:  Victor M Lu; Evan M Luther; Daniel G Eichberg; Alexis A Morell; Ashish H Shah; Ricardo J Komotar; Michael E Ivan
Journal:  J Neurooncol       Date:  2021-10-04       Impact factor: 4.130

6.  Are we over treating Pineal Parenchymal tumour with intermediate differentiation? Assessing the role of localised radiation therapy and literature review.

Authors:  P Das; S Mckinstry; A Devadass; B Herron; D S Conkey
Journal:  Springerplus       Date:  2016-01-12

7.  Role of Hypofractionated Stereotactic Radiosurgery in Recurrent Pineal Parenchymal Tumors of Intermediate Differentiation: A Case Report and Review of the Literature.

Authors:  Caglayan Selenge Beduk Esen; Gozde Yazici; Mustafa Berker; Faruk Zorlu
Journal:  Cureus       Date:  2020-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.